Loading
Processa Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 01 May 2026.
Processa Pharmaceuticals, Inc.: what insiders have been doing
This page follows insider dealings at Processa Pharmaceuticals, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, 27 filings were filed, from 9 insiders.
Only purchases show up on the open market, 21 purchases in all worth €88k, filed by 9 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a purchase of €5,090 by Skibsted Russell, published on 1 April 2026. Among those who bought: 6 senior executives, 2 chief executives and 1 finance chief.
Within a 30-day window, 21 purchases overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 1 May 2026, 170 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4.
For context, the typical company on the same exchange (median of 5,813 companies) published 19 filings over the same period, against 27 filings here. Since 2021, the database holds 42 purchases and 4 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
119
Thresholds
n/a
Buy Volume
€631,902
42 ops. · all time
Sell Volume
€367,982
4 ops. · all time
Who traded when
BuySaleGeorge K. Ng6 buys
David Young4 buys
Patrick Lin4 buys
Russell Skibsted3 buys
Sian Bigora3 buys
Wendy Guy3 buys
+4 other insiders
Since the insiders bought
- -19.8%Entry US$2.68 · Close at T+90 US$2.15
- -19.8%Entry US$2.68 · Close at T+90 US$2.15
- -19.8%Entry US$2.68 · Close at T+90 US$2.15
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.68
Analyst consensus
Income statement
EBITDA-US$14M
Net income-US$13.6M0.0% margin
Valuation
PER (trailing)2.5x
P/Book2.2x
Beta1.20
Balance sheet & cash
Market capUS$4.7M
Free Cash Flow-US$12.2M
Profitability & ownership
ROE-464.2%
ROA-156.8%
% insiders14.8%
% institutions18.7%
Last declaration on 11 August 2026
Declarations119 total
1,600 sharesCommon StockSEC:0000897069-26-001602:0
203 sharesCommon StockSEC:0000897069-26-001466:0
2,034 shares@ US$2.690.092% mcap3.1% of flowCommon StockSEC:0000897069-26-001006:0
Canonical exit: 29 Jul 2026 (T+90)
1,986 shares@ US$2.690.090% mcap33.3% of flowCommon StockSEC:0000897069-26-001000:0
Canonical exit: 29 Jul 2026 (T+90)
1,511 shares@ US$2.690.068% mcap2.7% of flowCommon StockSEC:0000897069-26-001004:0
Canonical exit: 29 Jul 2026 (T+90)
2,190 shares@ US$2.690.099% mcap33.3% of flowCommon StockSEC:0000897069-26-001008:0
Canonical exit: 29 Jul 2026 (T+90)
1,706 shares@ US$2.690.077% mcap1.0% of flowCommon StockSEC:0000897069-26-001010:0
Canonical exit: 29 Jul 2026 (T+90)
1,843 shares@ US$2.970.091% mcap3.0% of flowCommon StockSEC:0000897069-26-000910:0
Canonical exit: 14 Jul 2026 (T+90)
1,984 shares@ US$2.970.098% mcap33.0% of flowCommon StockSEC:0000897069-26-000902:0
Canonical exit: 14 Jul 2026 (T+90)
1,799 shares@ US$2.970.089% mcap33.0% of flowCommon StockSEC:0000897069-26-000904:0
Canonical exit: 14 Jul 2026 (T+90)
1,369 shares@ US$2.970.068% mcap2.7% of flowCommon StockSEC:0000897069-26-000908:0
Canonical exit: 14 Jul 2026 (T+90)
1,545 shares@ US$2.970.076% mcap1.0% of flowCommon StockSEC:0000897069-26-000912:0
Canonical exit: 14 Jul 2026 (T+90)
789 shares@ US$2.535100.0% of flowCommon StockSEC:0000897069-26-000781:0
Canonical exit: 29 Jun 2026 (T+90)
1,603 shares@ US$2.5352.8% of flowCommon StockSEC:0000897069-26-000747:0
Canonical exit: 29 Jun 2026 (T+90)
1,810 shares@ US$2.5351.0% of flowCommon StockSEC:0000897069-26-000756:0
Canonical exit: 29 Jun 2026 (T+90)
2,269 shares@ US$2.53534.7% of flowCommon StockSEC:0000897069-26-000741:0
Canonical exit: 29 Jun 2026 (T+90)
2,107 shares@ US$2.53533.7% of flowCommon StockSEC:0000897069-26-000743:0
Canonical exit: 29 Jun 2026 (T+90)
2,136 shares@ US$2.5353.1% of flowCommon StockSEC:0000897069-26-000750:0
Canonical exit: 29 Jun 2026 (T+90)
2,072 shares@ US$2.53583.6% of flowCommon StockSEC:0000897069-26-000752:0
Canonical exit: 29 Jun 2026 (T+90)
2,324 shares@ US$2.53533.7% of flowCommon StockSEC:0000897069-26-000754:0
Canonical exit: 29 Jun 2026 (T+90)
49 shares0Common StockSEC:0000897069-26-000224:0
25 of 119 declarations
About Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. (ticker: PCSA) is a U.S.-listed biotech company traded on the NASDAQ market in the United States. Headquartered in Hanover, Maryland, the company is a small-cap clinical-stage pharmaceutical developer focused on unmet medical needs, with a particular emphasis on oncology and other difficult-to-treat conditions. Processa was founded in 2017, following the reorganization of earlier Promet Therapeutics-related structures, and it has built its strategy around a “regulatory science” approach aimed at improving both efficacy and tolerability of drug candidates. ([processapharmaceuticals.com](https://www.processapharmaceuticals.com/?utm_source=openai))
The business model is centered on advancing a pipeline of development-stage assets rather than on an established commercial revenue base. In its own materials, Processa describes itself as a development-stage pharmaceutical company seeking to create next-generation therapies for patients with limited treatment options. As a result, its competitive position is driven less by current sales and more by scientific execution, clinical trial design, regulatory credibility, and the ability to secure financing over time. The company highlights that its development team has participated in numerous FDA approvals and meetings, which is a meaningful capability for a biotech of this size. ([processapharmaceuticals.com](https://www.processapharmaceuticals.com/investors/company-information?utm_source=openai))
Read moreShow less
From a product perspective, Processa focuses on drug candidates designed to deliver a better benefit-risk profile than existing therapies, especially in oncology. The company has described its programs as “next generation chemotherapies” and has referenced principles associated with the FDA’s Project Optimus initiative, reflecting an emphasis on dose optimization and reduced treatment discontinuation from adverse effects. This places Processa in a specialized, high-risk, high-upside niche of clinical development. ([processapharmaceuticals.com](https://www.processapharmaceuticals.com/investors/news-events/press-releases/detail/126/processa-pharmaceuticals-provides-product-pipeline-and?utm_source=openai))
Geographically, Processa’s footprint is primarily U.S.-based, which is typical for a clinical-stage biotech without a broad commercial platform. Its international presence remains limited at this stage; investor focus therefore rests on pipeline progress, regulatory milestones, and capital access rather than geographic expansion. ([processapharmaceuticals.com](https://www.processapharmaceuticals.com/?utm_source=openai))
Recent milestones have included equity financing activity, notably a public offering announced in January 2025, as well as an amended annual report filing for fiscal 2025 in March 2026. These events underscore a balance sheet that still relies on the capital markets, a common feature among development-stage biopharmaceutical companies. For investors in France, Belgium, and Switzerland, PCSA should therefore be viewed as a speculative clinical-stage name rather than a mature cash-generating healthcare company. ([processapharmaceuticals.com](https://www.processapharmaceuticals.com/investors/sec-filings/all-sec-filings/content/0001493152-25-004298/0001493152-25-004298.pdf?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
